ATE320264T1 - Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung - Google Patents

Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung

Info

Publication number
ATE320264T1
ATE320264T1 AT97953216T AT97953216T ATE320264T1 AT E320264 T1 ATE320264 T1 AT E320264T1 AT 97953216 T AT97953216 T AT 97953216T AT 97953216 T AT97953216 T AT 97953216T AT E320264 T1 ATE320264 T1 AT E320264T1
Authority
AT
Austria
Prior art keywords
vaccine
overexpressing
production
antigen
organism
Prior art date
Application number
AT97953216T
Other languages
English (en)
Inventor
Stephen M Boyle
Silvio Cravero
Lynette Corbeil
Gerhardt G Schurig
Nammalwar Srirnaganathan
Ramesh Vemulapalli
Original Assignee
Virginia Tech Intell Prop
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Tech Intell Prop, Univ California filed Critical Virginia Tech Intell Prop
Application granted granted Critical
Publication of ATE320264T1 publication Critical patent/ATE320264T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/23—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Brucella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT97953216T 1997-12-05 1997-12-05 Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung ATE320264T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNB971825173A CN1321693C (zh) 1997-12-05 1997-12-05 一种过量表达的同源抗原疫苗及其制备方法
PCT/US1997/023032 WO1999029340A1 (en) 1997-12-05 1997-12-05 An over-expressing homologous antigen vaccine and a method of making the same
OA1200000163A OA11421A (en) 1997-12-05 2000-06-05 An over-expressing homologous antigen vaccine and a method of making the same.
US09/692,623 US6811787B1 (en) 1997-12-05 2000-10-20 Over-expressing homologous antigen vaccine and a method of making the same

Publications (1)

Publication Number Publication Date
ATE320264T1 true ATE320264T1 (de) 2006-04-15

Family

ID=39591168

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97953216T ATE320264T1 (de) 1997-12-05 1997-12-05 Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung

Country Status (12)

Country Link
US (2) US6149920A (de)
EP (1) EP1035863B1 (de)
CN (1) CN1321693C (de)
AT (1) ATE320264T1 (de)
AU (1) AU759776C (de)
BR (1) BR9714904B1 (de)
CA (1) CA2317806A1 (de)
ES (1) ES2259449T3 (de)
NZ (1) NZ504993A (de)
OA (1) OA11421A (de)
PT (1) PT1035863E (de)
WO (1) WO1999029340A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE320264T1 (de) 1997-12-05 2006-04-15 Virginia Tech Intell Prop Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung
WO2002080964A1 (en) * 2001-04-06 2002-10-17 Institut Pasteur Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of vibrio cholerae 0139 bound to tetanus toxoid
US7416878B2 (en) * 2002-12-12 2008-08-26 The United States Of America As Represented By The Secretary Of The Army Immunogenic compositions including rough phenotype Brucella host strains and complementation DNA fragments
US7364745B2 (en) * 2004-02-06 2008-04-29 Virginia Tech Intellectual Properties, Inc. Development of a live, attenuated, recombinant vaccine for Brucellosis
WO2005084706A1 (en) * 2004-03-03 2005-09-15 Walter Reed Army Institute Of Research Mutant strains of brucella melitensis and immunogenic compositions
US20060115494A1 (en) * 2004-12-01 2006-06-01 Ronggai Sun Recombinant BCG strains with attenuated immunosuppressive properties

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US5468485A (en) * 1987-06-04 1995-11-21 Washington University Avirulent microbes and uses therefor
US6043057A (en) 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
CA2156191A1 (en) 1993-02-22 1994-09-01 Stephen B. Calderwood Heterologous antigens in live cell vaccine strains
ATE335083T1 (de) * 1993-02-26 2006-08-15 Novozymes As Methode und system zur erhöhten produktion von kommerziell wichtigen exoproteinen in gram- positiven bakterien
ES2171454T3 (es) 1993-06-04 2002-09-16 Whitehead Biomedical Inst Proteinas de estres y sus usos.
WO1998023763A1 (en) 1996-11-29 1998-06-04 The General Hospital Corporation Heterologous antigens in live cell v. cholerae strains
AU6969798A (en) * 1997-04-15 1998-11-11 Baylor College Of Medicine (pasteurella haemolytica) vaccine
ATE320264T1 (de) * 1997-12-05 2006-04-15 Virginia Tech Intell Prop Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung

Also Published As

Publication number Publication date
EP1035863A4 (de) 2003-04-16
OA11421A (en) 2004-04-21
AU759776B2 (en) 2003-05-01
EP1035863A1 (de) 2000-09-20
BR9714904A (pt) 2001-11-27
AU5701398A (en) 1999-06-28
AU759776C (en) 2004-05-20
US6149920A (en) 2000-11-21
US6811787B1 (en) 2004-11-02
CN1290173A (zh) 2001-04-04
CA2317806A1 (en) 1999-06-17
BR9714904B1 (pt) 2010-07-13
WO1999029340A1 (en) 1999-06-17
ES2259449T3 (es) 2006-10-01
CN1321693C (zh) 2007-06-20
NZ504993A (en) 2002-11-26
PT1035863E (pt) 2006-07-31
EP1035863B1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
ATE425987T1 (de) Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung
DE60016461D1 (de) Verfahren zur behandlung von glassubstraten und glassubstraten zur herstellung von anzeigeschirmen
ATE107608T1 (de) Kieselsäuresole, verfahren zur herstellung von kieselsäuresolen sowie verwendung der sole.
ATE439380T1 (de) Methoden zur herstellung humaner monoklonaler antikörper
GR3034349T3 (en) Neutralizing monoclonal antibodies to respiratory syncytial virus
FI960268A0 (fi) Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
ATE320264T1 (de) Ein impfstoff mit einem überexprimierenden homologen antigen sowie verfahren zu dessen herstellung
PH12020500662A1 (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
ATE148708T1 (de) Verfahren zur reinigung von waessrigen extrakten, die allergenische proteine enthalten, so erhaltene extrakte und ihre verwendung
NZ310195A (en) Inhibin compositions and methods of enhancing production performance
ATE204905T1 (de) Verfahren zur herstellung von äthylalkohol
DE69824839D1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5-halogen-pyridinen, verwendbar als cox-2 inhibitoren
AU2003263712A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
ATE187440T1 (de) Verfahren zur herstellung von substituierten 3- aminobenzonitrilen
ATE316135T1 (de) Monoklonale antikörper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung sowie ihre verwendung
NO970030L (no) Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2
ATE191457T1 (de) Verfahren zur herstellung von einem bicyclohexanderivat
GR930100091A (el) Μέ?οδος παραγωγής ελαιολάδου.
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
ATE131488T1 (de) Neues verfahren zur herstellung von hydrocortison sowie zwischenprodukten dafür
IT1275909B1 (it) Frammento di dna codificante d-amminoacido ossidasi
ATE43610T1 (de) Acino-foetale differenzierungsproteine verbunden mit krebs des pankreas, antiserum und monoklonale antikoerper gegen diese proteine und verfahren zu ihrer herstellung.
ATE185789T1 (de) Verfahren zur veredelung von sic-heizstäben

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties